It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

And, regardless of whether Merck enters the 2025-2026 RSV season with clesrovimab as planned, “2025 will be a year of growth for Beyfortus,” the CFO stressed. Since its approval last July ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

In the RSV market for infants, AstraZeneca and Sanofi’s Beyfortus leads the way. It achieved sales of 547 million euros ($592 million) in 2023. While cross-trial comparisons carry inherent ...

Beyfortus® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus® is also indicated for ...

With cold and flu season around the corner, Doctors recommend receiving the RSV vaccine ahead of the holidays.

Beyfortus is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season. Sanofi noted that ...

Doctors said the RSV vaccine is only given between the months of October and March because that’s when the season is expected ...

Beyfortus® is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season.ii As RSV ...

Beyfortus ® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus ® is also indicated for children up ...